See today's BioWorld MedTech
To read the full story, subscribe or sign in.

FDA expands Edwards’ TAVR to asymptomatic severe aortic stenosis

May 1, 2025
By Annette Boyle
In a significant boost to the Edwards Lifesciences Corp. Sapien 3 platform’s market opportunity, the U.S. FDA approved use of the transcatheter aortic valve replacement in patients with asymptomatic aortic stenosis.
BioWorld MedTech Regulatory Cardiovascular TAVR FDA